Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1995-03-31
1997-04-15
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 165, 514263, 514260, 536 2854, 536 2855, A61K 5100, A61M 3614
Patent
active
056206763
ABSTRACT:
The present invention provides certain novel adenosine triphosphate (ATP) analogs, pharmaceutical compositions, and methods of using such analogs in the treatment of septic shock and other disease conditions. Examples of the ATP analogs include the mono-, di- and triphosphates of adenosines with various selected substituents at the 2, 6, 8, and 9-positions, such as alkyl, alkylphenyl, phenylalkyl, S-alkyl, S-alkenyl, S-alkylcyano, S-phenyl, S-alkylphenyl, S-alkylamino, S-alkylthioalkyl, S-alkylthiocyanato, S-alkylaminophenyl, S-alkylnitrophenyl, hydroxy, bromo, fluoro, chloro, and aminoalkylamino. The present invention also provides pharmaceutical compositions of and methods of using certain xanthine and uracil derivatives for the above disease conditions. Examples of the xanthine derivatives include xanthines having alkyl or alkyltriphosphate substituents at the 1, 3, and 7-positions. Examples of the uracil derivatives include 5-fluoro- and 5-bromo uracil triphosphates. Also provided are assays for assessing the binding of the ATP analogs.
REFERENCES:
patent: 3998953 (1976-12-01), Konz et al.
patent: 4340728 (1982-07-01), Endo et al.
patent: 4883801 (1989-11-01), Nathanson
patent: 5051426 (1991-09-01), Parnell
patent: 5082845 (1992-01-01), Wolf et al.
patent: 5112827 (1992-05-01), Saunders et al.
patent: 5169849 (1992-12-01), Kiechel et al.
patent: 5219858 (1993-06-01), Parnell
patent: 5288701 (1994-02-01), Klein et al.
patent: 5314890 (1994-05-01), Agostini et al.
patent: 5340813 (1994-08-01), Klein et al.
patent: 5354756 (1994-10-01), Underiner et al.
patent: 5366977 (1994-11-01), Pollard et al.
patent: 5436143 (1995-07-01), Human
patent: 5446031 (1995-08-01), Sakata et al.
patent: 5470579 (1995-11-01), Bonte et al.
patent: 5470878 (1995-11-01), Michnick et al.
patent: 5473070 (1995-12-01), Underiner et al.
patent: 5478831 (1995-12-01), Furrer et al.
Kim et al. J. Med. Chem. (1994), vol. 37, pp. 3373-3382. "Structure-Activity Relationships of 1,3-dialkylxanthine Derivative at Rat A3 Adenosine Receptors".
Nem ckov a et al. Monatshefte f ur Chemie, vol. 126, pp. 799-804 (1995). "7-Substituted 8-Vinyl-1,3-dimethyl-3,7-dihydro-1-H-purine-2,6-diones and their Broncholytic Activity".
Hesek and Rybar. Monatshefte f ur Chemie, vol. 125, pp. 1273-1278 (1994). "[f]-Fused Purine-2,6-diones:Synthesis of New [1,3,5]-and [1,3,6]-Thiadiaze-pino-[3,2-f]-purine Ring Systems".
Gungor et al. J. Med. Chem. (1994) vol. 37, pp. 4307-4316 "N6-Substituted Adenosine Receptor Agonist. Synthesis and Pharmocological Activity as Potent Antinociceptive Agents".
Kinouchi et al. Stroke (Dallas) (1990), vol 21. No. 9, pp. 1326-1332 "Phenytoin Affects Metabolism of Free Fatty Acids and Nucleotides in Rat Cerebral Ischemia".
Dox et al. The Harper Collins Illustrated Medical Dictionary (1993) p. 432.
Jacobson et al. Biochemistry (1995), vol. 34, pp. 9088-9094. "Stimulation by Alkylxanthines of Chloride Efflux in CFPAC-1 Cells Does Not Involve A.sub. 1 Adenosine Receptors".
Jacobson (1990), Comprehensive Medicinal Chemistry, vol. 3, pp. 601-642, "Adenosine (P.sub.1) and ATP (P.sub.2) Receptors".
Satchell et al. (1975). J. Pharmacol. Exp. Ther., vol. 35, No. 3, pp. 540-548. "Inhibitory Effects of Adenine Nucleotide Analogs on the Isolated Guinea-Pig Taenia Coli".
St. Claire, III (1991). Anal. Chem., vol. 63, pp. 2657-2660. "Two Dimensional Ion Pairing Reverse Phase Chromatography of Nucleosides and Nucleotides on Polymeric and Silica Stationary Phase Supports".
Cusack et al. (1990), Annuals of New York Academy of Sciences, vol. 603, pp. 172-181, "Subtypes of P.sub.2 -purinoceptors".
Daly (1982), J. Medicinal Chemistry, vol. 25, No. 3, pp. 197-207, "Adenosine Receptors: Targets for Future Drugs".
Fedan et al. (1986), European Journal of Pharmacology, vol. 129, pp. 279-291, "Further comparison of contractions of the smooth muscle of the guinea pig isolated vas deferens induced by ATP and related analogs".
Jacobson et al. (1992). Journal of Medicinal Chemistry, vol. 35, No. 3, pp. 407-422, "Adenosine Receptors: Pharmacology, Structure Activity Relationships, and Therapeutical Potential".
Abbracchio et al (1993). Drug Development Research, vol. 28, pp. 207-213, "Purinoceptor Nomenclature: A Status Report".
Bo et al (1993). Triphosphate, the Key Structure of the ATP Molecule Responsible for Interaction With P.sub.2x -Purinoceptors, Gen. Pharmac. vol. 24, No. 3. pp. 637-640.
Boyer et al (1989). J. Biological Chemistry, vol. 264, No. 2, pp. 884-890, "Kinetics of Activation of Phospholipase C. by P.sub.24 Purinergic Receptor Agonists and Guanine Nucleotides".
Bruns (1991). Nucleosides & Nucleotides, vol. 10, No. 5, pp. 931-943, "Role of Adenosine in Energy Supply/Demand Balance".
Bwinstock (1991), Nucleosides & Nucleotides, vol. 10, No. 5, pp. 917-930, "Distribution and Roles of Purinoceptor Subtypes".
Bwinstock et al (1987). J. Pharmac., vol. 90, pp. 383-391, "P.sub.2 -purinoceptors of two subtypes in the rabbit mesenteric artery: reactive blue 2 selectively inhibits responses mediated via the P.sub.24 -but not the P.sub.2x -purinoceptor".
Cysack (1993). Drug Development Research, vol. 28, pp. 244-252, ".sub.2 receptor: Subclassification and Structure Activity Relationships".
Cusak et al (1991), Nucleosides and Nucleotides, vol. 10, No. 5, pp. 1019-1028, "Design, Syntheses, and Pharmacology of ATP Analogues Selective for Subtypes of P.sub.2 -purinoceptors".
Fischer Bilha
Jacobson Kenneth A.
Maillard Michel
Jones Dameron L.
Kight John
The United States of America as represented by the Department of
LandOfFree
Biologically active ATP analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biologically active ATP analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active ATP analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-358726